1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €4.32 (+182.35%). The median is €4.32 (+182.35%).
| Buy |
3 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
NeuroOne Medical: Q3 2026 revenue rises, losses widen and shares fall
NeuroOne Medical reported Q3 2026 product revenue up 16% to $2.0 million and order intake of $2.7 million (+43%), while gross margin improved to 59.9%. Net loss widened to $2.0 million, cash fell to $2.0 million, and the shares recently dropped about 3.95% to $1.46. Management expects 2026 revenues of $9.2–10.5 million and order intake of around $11.2 million, plans a second production site for H1 2027, and cites ISO‑13485 certification as a growth driver. » More on de.investing.com
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 1.73M | 20.15% |
| Gross profit | 1.04M | 33.50% |
| Net profit | -1.76M | 38.06% |
| EBITDA | -1.72M | 42.01% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €14.87M |
Number of shares | 8.7M |
52-week high/low | €6.01 - €1.23 |
| Dividends | No |
Beta | 0.64 |
P/E ratio | -2.17 |
PEG ratio | 0.02 |
P/B ratio | 4.55 |
P/S ratio | 1.72 |
Company profile
| Name | NeuroOne Medical Technologies Corp |
| CEO | David A. Rosa |
| Employees | 18 |
Discover assets
Shareholders of NeuroOne Medical Technologies Corp also invest in the following assets
